Jefferies Global Healthcare Conference
Logotype for Harrow Inc

Harrow (HROW) Jefferies Global Healthcare Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Harrow Inc

Jefferies Global Healthcare Conference summary

18 Nov, 2026

Financial performance and balance sheet

  • Five-year revenue CAGR exceeded 40% and adjusted EBITDA CAGR exceeded 60%; FY26 revenue guidance is $350m–$365m.

  • Q3 2026 record revenue exceeded $99m, including $83.5m of branded revenue at ~80% gross margin; period-end cash was ~$75m.

  • Q4 adjusted EBITDA guidance is >$33m, versus $21.2m recently reported.

  • $300m of unsecured notes carry an 8.625% coupon and are due in ~4 years.

Core brand performance

  • VEVYE Q3 revenue was ~$40m, up 75% YoY; prescriptions rose 83% YoY and revenue grew 35% sequentially; 10.7m additional commercial lives are expected from Jan. 1, 2027.

  • IHEEZO Q3 revenue exceeded $25m, up 15%, with unit demand up 21%; a 25% net price increase took effect July 1, 2026, and Q4 is expected to be its strongest quarter yet.

  • IHEEZO lost cataract-surgery pass-through status at end-Q1 2026, removing that market; Q3 unit demand still grew 21% YoY after an initial demand decline of >20%.

  • TRIESENCE Q3 revenue exceeded $10m, up 186%, with unit demand up 110%; coverage exceeds 95% and patient out-of-pocket cost is ~$38.

  • TRIESENCE phase IV cataract-surgery data are expected in H1 2027; a next-generation version is targeted for NDA filing in 2027 and launch in 2028 or early 2029.

Operating leverage and commercial platform

  • SG&A as a share of revenue declined from 84% in H1 2026 to 54% in Q3; Q2-to-Q3 SG&A was flat as revenue increased ~$28m, with $22m reaching the profit line.

  • Revenue is expected to outgrow costs, with operating leverage potentially increasing over coming quarters.

  • Four commercial teams cover ocular surface, retina, surgery, and compounded medications; planned launches through 2030 are intended to use existing teams and add one product each year.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Harrow